Medical grade honey: Hope for wounded white rhinos

Antimicrobial Properties of Hive Products and Their Potential Applications in Human and Veterinary Medicine

Hive products, encompassing honey, propolis, bee venom, royal jelly, and pollen, are recognized for their antimicrobial and therapeutic properties. This review examines their chemical composition, explores their mechanisms of action, and discusses their potential applications in both human and veterinary medicine, particularly in addressing the challenge of antimicrobial resistance. This study utilized a comprehensive literature search strategy, gathering data from Google Scholar, MEDLINE PubMed, SciELO, and SCOPUS databases. Relevant search terms were employed to ensure a thorough retrieval of the pertinent literature. Honey, rich in bioactive compounds such as hydrogen peroxide and methylglyoxal, effectively disrupts biofilms and combats multi-drug-resistant pathogens, showing promise in treating a range of infections. Propolis, with its flavonoids and phenolic acids, demonstrates synergistic effects when used in conjunction with antibiotics. Bee venom, particularly its component melittin, exhibits antibacterial and immunomodulatory properties, although further research is needed to address toxicity concerns. Pollen and royal jelly demonstrate broad-spectrum antimicrobial activity, which is particularly relevant to animal health. Existing pre-clinical and clinical data support the therapeutic potential of these hive products. Hive products represent a vast and largely untapped natural resource for combating antimicrobial resistance and developing sustainable therapies, particularly in the field of veterinary medicine. However, challenges remain due to the inherent variability in their composition and the lack of standardized protocols for their preparation and application. Further research is essential to fully elucidate their mechanisms of action, optimize formulations for enhanced efficacy, and establish standardized protocols to ensure their safe and effective clinical use.

Medical-Grade Honey Outperforms Conventional Treatments for Healing Cold Sores-A Clinical Study

Cold sores are nasolabial blisters caused by herpes simplex virus (HSV) infections. Novel therapies demonstrating simultaneously antiviral activity and improved wound healing are warranted. The aim of this study was to investigate the efficacy of medical-grade honey (MGH) for treating HSV-induced cold sores. A crossover trial was performed in patients with recurrent cold sores (n = 29). The majority (65.6%) of these patients experience four or more episodes per year, thus forming a valid self-control group. In this study, patients applied an MGH-based formulation (L-Mesitran Soft) on their cold sore at the onset of symptoms (62.1%) or appearing of blister (37.9%) and compared it to their conventional treatments. After complete healing, patients filled in a questionnaire evaluating healing, pain, and itching. The average absolute healing time was 72.4% slower with conventional treatment (10.0 days) compared to MGH (5.8 days). After MGH treatment, 86.2% of all patients experienced faster objective healing (6.9% similar and 6.9% slower) and the subjective healing score was higher in 79.3% of the patients (20.7% similar). If the patients normally experience pain and itching during their cold sores, these levels were lower with MGH therapy compared to conventional treatment in 72.7% and 71.4% of the patients, respectively. Moreover, 100% of the patients prefer MGH treatment over conventional treatment and will use it again on future cold sores. MGH is a promising alternative treatment for cold sores, likely by combining both increased antiviral and wound healing activities while alleviating pain and itching.